Diagnostics

Abbott, OraSure enter distribution agreement for OraQuick Rapid HIV-1 test

Published in AIDS Weekly, July 22nd, 2002

Abbott Laboratories (ABT) and OraSure Technologies (OSUR) announced agreements for the coexclusive distribution of OraSure Technologies' OraQuick rapid test for the detection of antibodies to the human immunodeficiency virus type 1 (HIV-1) and for a nonexclusive sublicense of certain lateral-flow patents for which Abbott is the exclusive licenser.

OraQuick is a rapid, point-of-care test designed to detect antibodies to HIV-1 within 20 minutes, and is the only rapid device in the world designed to use oral fluid and whole blood samples. In June 2001, OraSure submitted an application to the U.S. Food and Drug Administration (FDA) for premarket approval of the OraQuick...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-07-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry